Wearable Tech for Early Detection of CRS in CAR T-cell Therapy | Sridevi Rajeeve, MD | IMS 2023

Wearable Tech for Early Detection of CRS in CAR T-cell Therapy | Sridevi Rajeeve, MD | IMS 2023
Real World Experiences of Patients Treated with Teclistamab | Shonali Midha, MD | IMS 2023
Using IMIDS and PIs to Treat at First Relapse | Paul Richardson, MD | IMS 2023
Immune Based Strategies to Improve Outcomes of Cellular Therapies | Rakesh Popat, PhD | IMS 2023
IMS Highlights for Triple Class Refractory Myeloma | Sagar Lonial, MD, FACP | IMS 2023
Optimizing Imaging in Multiple Myeloma | Jens Hillengass, MD | IMS 2023
A Comparative Study of Disparities in Myeloma Treatment Access | Matthew Leblanc, PHD, RN | IMS 2023
Managing CART-Cell Therapy in the Real World | Yi Lin, MD, PhD | IMS 2023
Results from the GMMG Concept Trial in Germany | Lisa Leypoldt, MD | IMS 2023
Changes in Weight in Induction Therapy | Ross Firestone, MD, PhD | IMS 2023
Charting the Genetic Evolution of Myeloma Cells | Faith Davies, MD | IMS 2023
Managing Renal Failure | Efstathious Kastritis, MD | IMS 2023
Individualizing Frontline Treatment to Get the Best Outcomes | Xavier Leleu, MD, PhD | IMS 2023
Key Take Aways from IMS 2023 | Rafael Fonseca, MD | IMS 2023
Impact of Racial Disparities in Myeloma | Doctors Cole and Kumar | IMS 2023